STEPHEN A WANK, M.D.
Osteopathic Medicine at Old Georgetown Rd, Bethesda, MD
License number
Maryland D0025066
Category
Osteopathic Medicine
Type
Emergency Medicine
Address
Address
2
8600 Old Georgetown Rd, Bethesda, MD 20814
10921 Edison Rd, Rockville, MD 20854
10921 Edison Rd, Rockville, MD 20854
Phone
(301) 896-3593
(301) 299-4194
(301) 299-4194
Personal information
See more information about STEPHEN A WANK at radaris.comName
Address
Phone
10921 Edison Rd, Potomac, MD 20854
10921 Edison Rd, Potomac, MD 20854
7612 Clarendon Rd, Bethesda, MD 20814
Professional information
See more information about STEPHEN A WANK at trustoria.com
Dr. Stephen A Wank, Bethesda MD - MD (Doctor of Medicine)
Dr. Stephen A Wank, Bethesda MD - MD (Doctor of Medicine)
Specialties:
Gastroenterology, Endocrinology & Metabolism, Endocrinology, Diabetes & Metabolism
Address:
9000 Rockville Pike SUITE 10, Bethesda 20892
8600 Old Georgetown Rd, Bethesda 20814
(301) 896-3593 (Phone), (301) 896-3100 (Fax)
8600 Old Georgetown Rd, Bethesda 20814
(301) 896-3593 (Phone), (301) 896-3100 (Fax)
Certifications:
Diabetes, Metabolism & Endocrinology, 1987, Gastroenterology, 1985, Internal Medicine, 1984
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
9000 Rockville Pike SUITE 10, Bethesda 20892
8600 Old Georgetown Rd, Bethesda 20814
Suburban Hospital
8600 Old Georgetown Rd, Bethesda 20814
8600 Old Georgetown Rd, Bethesda 20814
Suburban Hospital
8600 Old Georgetown Rd, Bethesda 20814
Education:
Medical School
Duke University
Graduated: 1977
The Johns Hopkins Hospital
Fell-Stanford U Hosp
National Institutes Of Health Clinical Center
Duke University
Graduated: 1977
The Johns Hopkins Hospital
Fell-Stanford U Hosp
National Institutes Of Health Clinical Center
Cloning And Functional Expression Of Cholecystokinin/Gastrin Receptor-Encoding Dna
Cloning And Functional Expression Of Cholecystokinin/Gastrin Receptor-Encoding Dna
US Patent:
6169173, Jan 2, 2001
Filed:
Mar 10, 1993
Appl. No.:
8/029170
Inventors:
Stephen A. Wank - Bethesda MD
Assignee:
The United States of America as represented by the Department of Health and
Human Services - Washington DC
Human Services - Washington DC
International Classification:
C12N 1512
US Classification:
536 235
Abstract:
An unconventional approach to purifying CCK receptor protein to sequenceable-grade homogeneity has been discovered. By this approach, CCK receptor protein can be obtained and sequenced routinely from a variety sources, and from the sequence information thus obtained it is possible to prepare oligonucleotides suitable for cloning CCK receptor genes. "CCK receptor" in this context denotes, any from a group of proteins that displays a characteristic CCK binding affinity and that is encoded by a nucleotide sequence which hybridizes a oligonucleotide probe designed in accordance with the criteria elaborated herein.
Cloning And Characterization Of Calcitonin Gene Related Peptide Receptors
Cloning And Characterization Of Calcitonin Gene Related Peptide Receptors
US Patent:
2004011, Jun 10, 2004
Filed:
May 16, 2003
Appl. No.:
10/440479
Inventors:
Joseph Pisegna - Santa Monica CA, US
Stephen Wank - Potomac MD, US
Stephen Wank - Potomac MD, US
Assignee:
The Regents of the University of California
International Classification:
C12Q001/68, C07H021/04, C07K014/705
US Classification:
435/006000, 435/069100, 435/320100, 435/325000, 530/350000, 536/023500
Abstract:
This invention provides CGRP receptors (including both amino acid and nucleic acid sequences). Compositions which include these polypeptides, proteins, nucleic acids, recombinant cells, transgenic animals, and antibodies to the receptors are also provided.
Use Of Pentagastrin To Inhibit Gastric Acid Secretion Or As A Diuretic
Use Of Pentagastrin To Inhibit Gastric Acid Secretion Or As A Diuretic
US Patent:
2008004, Feb 21, 2008
Filed:
Jul 30, 2007
Appl. No.:
11/830651
Inventors:
Joseph Pisegna - Santa Monica CA, US
Stephen Wank - Potomac MD, US
Stephen Wank - Potomac MD, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
A61K 38/16, A61K 38/08, A61P 1/00
US Classification:
514017000, 514002000
Abstract:
This invention pertains to the discovery that pentagastrin, when administered in conjunction with a proton pump inhibitor (PPI) is synergistic with the PPI and significantly increases the efficacy of the PPI in reducing/mitigating excess gastric acid secretion.
Method Of Purifying Cholecystokinin Receptor Protein
Method Of Purifying Cholecystokinin Receptor Protein
US Patent:
5319073, Jun 7, 1994
Filed:
Sep 2, 1992
Appl. No.:
7/937609
Inventors:
Stephen A. Wank - Bethesda MD
Assignee:
The United States of America, as represented by the Department of Health
& Human Services - Washington DC
& Human Services - Washington DC
International Classification:
C07K 302
US Classification:
530412
Abstract:
An unconventional approach to purifying CCK receptor protein to sequenceable-grade homogeneity has been discovered. By this approach, CCK receptor protein can be obtained and sequenced routinely from a variety sources, and from the sequence information thus obtained it is possible to prepare oligonucleotides suitable for cloning CCK receptor genes. "CCK receptor" in this context denotes any from a group of proteins that displays a characteristic CCK binding affinity and that is encoded by a nucleotide sequence which hybridizes a oligonucleotide probe designed in accordance with the criteria elaborated herein.
Use Of Pentagastrin To Inhibit Gastric Acid Secretion Or As A Diuretic
Use Of Pentagastrin To Inhibit Gastric Acid Secretion Or As A Diuretic
US Patent:
7807623, Oct 5, 2010
Filed:
Dec 8, 2006
Appl. No.:
11/608667
Inventors:
Joseph R. Pisegna - Santa Monica CA, US
Stephen Wank - Potomac MD, US
Stephen Wank - Potomac MD, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 38/00, A61K 49/00
US Classification:
514 2, 514 13, 514 17, 514199, 514256, 514338, 514361, 530300, 530326, 530330, 424 91
Abstract:
This invention pertains to the discovery administration of a CCK receptor agonist can increase urinary sodium excretion and/or free water excretion in a mammal. CCK receptor agonist can thereby be used in the treatment of conditions such high blood pressure, fluid retention associated with heart failure, fluid retention associated with acute or chronic kidney failure, fluid retention associated with cirrhosis, fluid retention associated with liver failure, calcium kidney stones, nephrogenic diabetes insipidus, and renal tubular acidosis.